<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35904151</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>495</StartPage><EndPage>502</EndPage><MedlinePgn>495-502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27691</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Improved functional outcome measures in amyotrophic lateral sclerosis (ALS) would aid ALS trial design and help hasten drug discovery. We evaluate the longitudinal performance of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) compared to the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised for Self-Entry (ALSFRS-RSE) as patient reported outcomes of functional status in people with ALS.</AbstractText><AbstractText Label="METHODS">Participants completed the ROADS and the ALSFRS-RSE questionnaires at baseline, 3-, 6-, and 12- mo using Research Electronic Data Capture as part of a prospective, longitudinal, remote, online survey study of fatigue in ALS from 9/2020 to 12/2021. The scales were compared cross-sectionally (at baseline) and longitudinally. Correlation coefficients, coefficients of variation, and descriptive statistics were assessed.</AbstractText><AbstractText Label="RESULTS">A total of 182 adults with ALS consented to the study. This volunteer sample was comprised of predominantly White, non-Hispanic, non-smoking participants. Consented participant survey completion was approximately 90% at baseline and greater than 40% at 12 mo. The ALSFRS-RSE and the ROADS had high, significant agreement at 3 and 6 mo by Cohen's kappa &#x2265;71% (p&#xa0;&lt;&#x2009;0.001); the number of functional increases or plateaus on the two scales were not significantly different; and the coefficient of variation of functional decline was similar at the 6-month mark, though higher for the ROADS at 3 mo and lower at 12 mo.</AbstractText><AbstractText Label="DISCUSSION">Although the ROADS performed similarly to the ALSFRS-RSE in an observational cohort, it has psychometric advantages, such as Rasch-modeling and unidimensionality. It merits further investigation as a patient reported outcome of overall disability and efficacy outcome measure in ALS trials.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-9058-4331</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-5820-5880</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheier</LastName><ForeName>Zoe A</ForeName><Initials>ZA</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keegan</LastName><ForeName>Mackenzie A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Alison P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Biostatistics Center, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Atlanta Veterans Administration Medical Center, Decatur, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Sean M. Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK2 CX001595</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="Y">Disabled Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">ALSFRS-RSE</Keyword><Keyword MajorTopicYN="N">ROADS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">outcome measure</Keyword></KeywordList><CoiStatement>SAJ has received research support from the ALS Association. JDB has received research support from Biogen, MT Pharma of America, MT Pharma Holdings of America, Transposon Therapeutics, Alexion, Rapa Therapeutics, ALS Association, Muscular Dystrophy Association, ALS One, Tambourine, ALS Finding a Cure. He has been a paid member of an advisory panel for Regeneron, Biogen, Clene Nanomedicine, MT Pharma of America, MT Pharma Holdings of America, Janssen, RRT. He received an honorarium for an educational event for Projects in Knowledge. He has unpaid roles on the advisory boards for the non&#x2010;profits Everything ALS and ALS One. The remaining authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35904151</ArticleId><ArticleId IdType="doi">10.1002/mus.27691</ArticleId><ArticleId IdType="pmc">PMC9804793</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999;169:13&#x2010;21. doi:10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS&#x2010;R score and its ratio: a useful predictor for ALS&#x2010;progression. J Neurol Sci. 2008;275:69&#x2010;73. 10.1016/j.jns.2008.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chio A. Evidence of multidimensionality in the ALSFRS&#x2010;R scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84:1340&#x2010;1345. 10.1136/jnnp-2012-304701</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, Ferro S, Group E. A further Rasch study confirms that ALSFRS&#x2010;R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:331&#x2010;337. 10.3109/21678421.2015.1026829</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Beukenhorst AL, Howells K, Cook L, et al. Engagement and participant experiences with consumer smartwatches for health research: longitudinal, observational feasibility study. JMIR Mhealth Uhealth. 2020;8:e14368. 10.2196/14368</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14368</ArticleId><ArticleId IdType="pmc">PMC7016619</ArticleId><ArticleId IdType="pubmed">32012078</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Paganoni S, Carlson K, et al. Design and results of a smartphone&#x2010;based digital phenotyping study to quantify ALS progression. Ann Clin Transl Neurol. 2019;6:873&#x2010;881. 10.1002/acn3.770</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.770</ArticleId><ArticleId IdType="pmc">PMC6529832</ArticleId><ArticleId IdType="pubmed">31139685</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew S, Burke KM, Collins E, et al. Patient reported outcomes in ALS: characteristics of the self&#x2010;entry ALS functional rating scale&#x2010;revised and the activities&#x2010;specific balance confidence scale. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:467&#x2010;477. 10.1080/21678421.2021.1900259</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1900259</ArticleId><ArticleId IdType="pubmed">33771057</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marchi F et al. Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. J Neurol. 2020;267:1754&#x2010;1759. 10.1007/s00415-020-09774-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09774-8</ArticleId><ArticleId IdType="pubmed">32125520</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808&#x2010;812. 10.1212/WNL.0000000000002251</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. The PRO&#x2010;ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719&#x2010;1725. 10.1212/WNL.0000000000000951</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy D, Severson K, Ghosh S, et al. Identifying patterns of ALS progression from sparse longitudinal data. medRxiv. 2021. 10.1101/2021.05.13.21254848</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.13.21254848</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes J, Levy G, Albert S, et al. Development and evaluation of a self&#x2010;administered version of the ALSFRS&#x2010;R. Neurology. 2006;67:1294&#x2010;1296. 10.1212/01.wnl.0000238505.22066.fc</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000238505.22066.fc</ArticleId><ArticleId IdType="pubmed">17030772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Rutkove SB, Caress JB, et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:555&#x2010;561. 10.1080/21678421.2018.1510008</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1510008</ArticleId><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindarajan R, Berry JD, Paganoni S, Pulley MT, Simmons Z. Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020;62:321&#x2010;326. 10.1002/mus.26921</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26921</ArticleId><ArticleId IdType="pubmed">32415876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al. Development and validation of the Rasch&#x2010;built overall amyotrophic lateral sclerosis disability scale (ROADS). JAMA Neurol. 2020;77:480&#x2010;488. 10.1001/jamaneurol.2019.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Hermans MCE, Faber CG, et al. Rasch&#x2010;ionale for neurologists. J Peripher Nerv Syst. 2015;20:260&#x2010;268. 10.1111/jns.12122</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12122</ArticleId><ArticleId IdType="pubmed">26115370</ArticleId></ArticleIdList></Reference><Reference><Citation>
Emory University School of Medicine, Department of Neurology
. 
Rasch Overall ALS Disability Scale (ROADS)
. Available online on July 22, 2022 at https://med.emory.edu/departments/neurology/programs_centers/emory_als_center/_documents/roads.pdf
</Citation></Reference><Reference><Citation>
American Association for Public Opinion Research
. 
AAPOR Code of Professional Ethics and Practices
. Available online on July 22, 2022 at https://www.aapor.org/Standards-Ethics/AAPOR-Code-of-Ethics.aspx
</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. 10.1016/j.jbi.2019.103208</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) &#x2013; a metadata&#x2010;driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377&#x2010;381. 10.1016/j.jbi.2008.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17:163&#x2010;170. 10.1179/jmt.2009.17.3.163</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/jmt.2009.17.3.163</ArticleId><ArticleId IdType="pmc">PMC2762832</ArticleId><ArticleId IdType="pubmed">20046623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer EM, Hacker S, Hautzinger M, Meyer TD, Kubler A. Validity of the ALS&#x2010;depression&#x2010;inventory (ADI&#x2010;12) &#x2013; a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord. 2008;109:213&#x2010;219. 10.1016/j.jad.2007.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2007.11.012</ArticleId><ArticleId IdType="pubmed">18262283</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shirley Ryan Abilitylab
. 
Fatigue Severity Scale
. Available online on July 22, 2022 at https://www.sralab.org/sites/default/files/2017-06/sleep-Fatigue-Severity-Scale.pdf
</Citation></Reference><Reference><Citation>Gibbons CJ, Mills RJ, Thornton EW, et al. Development of a patient reported outcome measure for fatigue in motor neurone disease: the neurological fatigue index (NFI&#x2010;MND). Health Qual Life Outcomes. 2011;9:101. 10.1186/1477-7525-9-101</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-9-101</ArticleId><ArticleId IdType="pmc">PMC3282643</ArticleId><ArticleId IdType="pubmed">22107756</ArticleId></ArticleIdList></Reference><Reference><Citation>
Center for Disease Control and Prevention
. 
National Amyotrophic Lateral Sclerosis (ALS) Registry
. Updated April 15, 2022. Available online on July 22, 2022 at https://www.cdc.gov/als/Default.html
</Citation></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis &#x2010; United States, 2012&#x2010;2013. MMWR Surveill Summ. 2016;65:1&#x2010;12. 10.15585/mmwr.ss6508a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.ss6508a1</ArticleId><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen KD, Kasarskis EJ, Bedlack RS, et al. The National Registry of veterans with amyotrophic lateral sclerosis. Neuroepidemiology. 2008;30:180&#x2010;190. 10.1159/000126910</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000126910</ArticleId><ArticleId IdType="pubmed">18421218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713&#x2010;1717. 10.1007/s00415-010-5609-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5609-1</ArticleId><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E&#x2010;surveys (CHERRIES). J Med Internet Res. 2004;6:e34. 10.2196/jmir.6.3.e34</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.6.3.e34</ArticleId><ArticleId IdType="pmc">PMC1550605</ArticleId><ArticleId IdType="pubmed">15471760</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>